Marina Jarschel Souza, J. Pereira, Ana Carolina De Souza Mangrich, Ana Paula Beltrame Farina Pasinato, Esther Buzaglo Dantas-Corrêa, L. Schiavon, J. Narciso-Schiavon
{"title":"非酒精性脂肪肝患者晚期纤维化相关因素","authors":"Marina Jarschel Souza, J. Pereira, Ana Carolina De Souza Mangrich, Ana Paula Beltrame Farina Pasinato, Esther Buzaglo Dantas-Corrêa, L. Schiavon, J. Narciso-Schiavon","doi":"10.52787/agl.v53i1.255","DOIUrl":null,"url":null,"abstract":"Introduction. Nonalcoholic fatty liver disease includes conditions such as nonalcoholic steatosis and nonalcoholic steatohepatitis, with varying degrees of fibrosis that can progress to cirrhosis and hepatocellular carcinoma. Although the gold standard for its diagnosis remains liver biopsy, many non-invasive methods have been proposed to aid in both the diagnosis of the disease and the evaluation of the presence of liver fibrosis, which is a strong and independent factor for liver related mortality.\nObjectives. The objectives of this study were: 1) to identify the clinical and laboratory features associated with the presence of advanced fibrosis in individuals with biopsy-confirmed nonalcoholic fatty liver disease; 2) to evaluate the performance of non-invasive markers in identifying patients with advanced fibrosis.\nMethods. A cross-sectional-analytic study that evaluated patients with nonalcoholic fatty liver disease treated in the outpatient clinic of a university hospital of reference in hepatology, between January 2013 and December 2016.\n Results. 81 patients aged 53.3 ± 9.8 years were included in this study; 39.5% were men and 70.1% were obese. When comparing patients with advanced fibrosis to those without advanced fibrosis, patients with advanced fibrosis had a lower proportion of males than females (17.6 vs. 45.4%, p = 0.038), a higher proportion of hypothyroidism (29.4 vs. 6.3%, p = 0.017) and a higher median AST (52 vs. 31 U/L, p = 0.005). In logistic regression analysis, only hypothyroidism was independently associated with advanced fibrosis (OR = 4.975; CI 95% 1.050 - 23.574; p = 0.043). Spearman correlation analysis showed that higher levels of fibrosis on liver biopsy, were associated with higher levels of TSH (r = 0.304; p = 0.036), AST (r = 0.277; p = 0.019), GGT (r = 0.284; p = 0.017) and LDL (r = 0.258; p = 0.037). Regarding the performance of the non-invasive markers, the area under the ROC curve of Fibrosis 4 score was 0.723 (p = 0.008), that of Nonalcoholic fatty liver disease fibrosis score was 0.713 (p = 0.022), that of gamma-glutamyl transferase platelet ratio was 0.697 (p = 0.019) and that of aspartate-to-alanine aminotransferase ratio was 0.689 (p = 0.031).\nConclusions. Hypothyroidism is a factor independently associated with advanced fibrosis. In the outpatient setting, non-invasive markers may be useful in identifying patients with advanced fibrosis.","PeriodicalId":270053,"journal":{"name":"Acta gastroenterológica latinoamericana","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Factors Associated with Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease\",\"authors\":\"Marina Jarschel Souza, J. Pereira, Ana Carolina De Souza Mangrich, Ana Paula Beltrame Farina Pasinato, Esther Buzaglo Dantas-Corrêa, L. Schiavon, J. Narciso-Schiavon\",\"doi\":\"10.52787/agl.v53i1.255\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction. Nonalcoholic fatty liver disease includes conditions such as nonalcoholic steatosis and nonalcoholic steatohepatitis, with varying degrees of fibrosis that can progress to cirrhosis and hepatocellular carcinoma. Although the gold standard for its diagnosis remains liver biopsy, many non-invasive methods have been proposed to aid in both the diagnosis of the disease and the evaluation of the presence of liver fibrosis, which is a strong and independent factor for liver related mortality.\\nObjectives. The objectives of this study were: 1) to identify the clinical and laboratory features associated with the presence of advanced fibrosis in individuals with biopsy-confirmed nonalcoholic fatty liver disease; 2) to evaluate the performance of non-invasive markers in identifying patients with advanced fibrosis.\\nMethods. A cross-sectional-analytic study that evaluated patients with nonalcoholic fatty liver disease treated in the outpatient clinic of a university hospital of reference in hepatology, between January 2013 and December 2016.\\n Results. 81 patients aged 53.3 ± 9.8 years were included in this study; 39.5% were men and 70.1% were obese. When comparing patients with advanced fibrosis to those without advanced fibrosis, patients with advanced fibrosis had a lower proportion of males than females (17.6 vs. 45.4%, p = 0.038), a higher proportion of hypothyroidism (29.4 vs. 6.3%, p = 0.017) and a higher median AST (52 vs. 31 U/L, p = 0.005). In logistic regression analysis, only hypothyroidism was independently associated with advanced fibrosis (OR = 4.975; CI 95% 1.050 - 23.574; p = 0.043). Spearman correlation analysis showed that higher levels of fibrosis on liver biopsy, were associated with higher levels of TSH (r = 0.304; p = 0.036), AST (r = 0.277; p = 0.019), GGT (r = 0.284; p = 0.017) and LDL (r = 0.258; p = 0.037). Regarding the performance of the non-invasive markers, the area under the ROC curve of Fibrosis 4 score was 0.723 (p = 0.008), that of Nonalcoholic fatty liver disease fibrosis score was 0.713 (p = 0.022), that of gamma-glutamyl transferase platelet ratio was 0.697 (p = 0.019) and that of aspartate-to-alanine aminotransferase ratio was 0.689 (p = 0.031).\\nConclusions. Hypothyroidism is a factor independently associated with advanced fibrosis. In the outpatient setting, non-invasive markers may be useful in identifying patients with advanced fibrosis.\",\"PeriodicalId\":270053,\"journal\":{\"name\":\"Acta gastroenterológica latinoamericana\",\"volume\":\"19 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta gastroenterológica latinoamericana\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52787/agl.v53i1.255\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta gastroenterológica latinoamericana","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52787/agl.v53i1.255","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
介绍。非酒精性脂肪性肝病包括非酒精性脂肪变性和非酒精性脂肪性肝炎,伴有不同程度的纤维化,可发展为肝硬化和肝细胞癌。尽管其诊断的金标准仍然是肝活检,但已经提出了许多非侵入性方法来帮助疾病的诊断和评估肝纤维化的存在,肝纤维化是肝脏相关死亡率的一个强大而独立的因素。本研究的目的是:1)确定与活检证实的非酒精性脂肪肝患者晚期纤维化相关的临床和实验室特征;2)评价非侵入性标志物在晚期纤维化患者识别中的作用。一项横断面分析研究评估了2013年1月至2016年12月在某大学肝病参考医院门诊治疗的非酒精性脂肪性肝病患者。结果:81例患者入组,年龄53.3±9.8岁;39.5%为男性,70.1%为肥胖。当将晚期纤维化患者与非晚期纤维化患者进行比较时,晚期纤维化患者的男性比例低于女性(17.6 vs. 45.4%, p = 0.038),甲状腺功能减退的比例较高(29.4 vs. 6.3%, p = 0.017),中位AST较高(52 vs. 31 U/L, p = 0.005)。在logistic回归分析中,只有甲状腺功能减退与晚期纤维化独立相关(OR = 4.975;Ci 95% 1.050 - 23.574;P = 0.043)。Spearman相关分析显示,肝活检中较高水平的纤维化与较高水平的TSH相关(r = 0.304;p = 0.036), AST (r = 0.277;p = 0.019), GGT (r = 0.284;p = 0.017)和LDL (r = 0.258;P = 0.037)。无创标志物方面,纤维化4评分的ROC曲线下面积为0.723 (p = 0.008),非酒精性脂肪肝纤维化评分的ROC曲线下面积为0.713 (p = 0.022), γ -谷氨酰转移酶血小板比值的ROC曲线下面积为0.697 (p = 0.019),天冬氨酸-丙氨酸转氨酶比值的ROC曲线下面积为0.689 (p = 0.031)。甲状腺功能减退是与晚期纤维化独立相关的因素。在门诊环境中,非侵入性标志物可能有助于识别晚期纤维化患者。
Factors Associated with Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
Introduction. Nonalcoholic fatty liver disease includes conditions such as nonalcoholic steatosis and nonalcoholic steatohepatitis, with varying degrees of fibrosis that can progress to cirrhosis and hepatocellular carcinoma. Although the gold standard for its diagnosis remains liver biopsy, many non-invasive methods have been proposed to aid in both the diagnosis of the disease and the evaluation of the presence of liver fibrosis, which is a strong and independent factor for liver related mortality.
Objectives. The objectives of this study were: 1) to identify the clinical and laboratory features associated with the presence of advanced fibrosis in individuals with biopsy-confirmed nonalcoholic fatty liver disease; 2) to evaluate the performance of non-invasive markers in identifying patients with advanced fibrosis.
Methods. A cross-sectional-analytic study that evaluated patients with nonalcoholic fatty liver disease treated in the outpatient clinic of a university hospital of reference in hepatology, between January 2013 and December 2016.
Results. 81 patients aged 53.3 ± 9.8 years were included in this study; 39.5% were men and 70.1% were obese. When comparing patients with advanced fibrosis to those without advanced fibrosis, patients with advanced fibrosis had a lower proportion of males than females (17.6 vs. 45.4%, p = 0.038), a higher proportion of hypothyroidism (29.4 vs. 6.3%, p = 0.017) and a higher median AST (52 vs. 31 U/L, p = 0.005). In logistic regression analysis, only hypothyroidism was independently associated with advanced fibrosis (OR = 4.975; CI 95% 1.050 - 23.574; p = 0.043). Spearman correlation analysis showed that higher levels of fibrosis on liver biopsy, were associated with higher levels of TSH (r = 0.304; p = 0.036), AST (r = 0.277; p = 0.019), GGT (r = 0.284; p = 0.017) and LDL (r = 0.258; p = 0.037). Regarding the performance of the non-invasive markers, the area under the ROC curve of Fibrosis 4 score was 0.723 (p = 0.008), that of Nonalcoholic fatty liver disease fibrosis score was 0.713 (p = 0.022), that of gamma-glutamyl transferase platelet ratio was 0.697 (p = 0.019) and that of aspartate-to-alanine aminotransferase ratio was 0.689 (p = 0.031).
Conclusions. Hypothyroidism is a factor independently associated with advanced fibrosis. In the outpatient setting, non-invasive markers may be useful in identifying patients with advanced fibrosis.